SE507028C2 - Ny medicinsk användning - Google Patents

Ny medicinsk användning

Info

Publication number
SE507028C2
SE507028C2 SE9602931A SE9602931A SE507028C2 SE 507028 C2 SE507028 C2 SE 507028C2 SE 9602931 A SE9602931 A SE 9602931A SE 9602931 A SE9602931 A SE 9602931A SE 507028 C2 SE507028 C2 SE 507028C2
Authority
SE
Sweden
Prior art keywords
use according
chitosan
medicament
heparin
present
Prior art date
Application number
SE9602931A
Other languages
English (en)
Swedish (sv)
Other versions
SE9602931L (sv
SE9602931D0 (sv
Inventor
Olle Larm
Marcus Back
Tomas Bergstroem
Original Assignee
Medicarb Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicarb Ab filed Critical Medicarb Ab
Priority to SE9602931A priority Critical patent/SE507028C2/sv
Publication of SE9602931D0 publication Critical patent/SE9602931D0/xx
Priority to AU37911/97A priority patent/AU705189B2/en
Priority to EP97934838A priority patent/EP0930885B1/en
Priority to PCT/SE1997/001320 priority patent/WO1998005341A1/en
Priority to NZ333925A priority patent/NZ333925A/xx
Priority to DK97934838T priority patent/DK0930885T3/da
Priority to JP10507859A priority patent/JP2000515543A/ja
Priority to CN97197038A priority patent/CN1227493A/zh
Priority to DE69711897T priority patent/DE69711897T2/de
Priority to AT97934838T priority patent/ATE215829T1/de
Priority to ES97934838T priority patent/ES2174273T3/es
Priority to US09/230,021 priority patent/US6207653B1/en
Priority to CA002261742A priority patent/CA2261742A1/en
Publication of SE9602931L publication Critical patent/SE9602931L/xx
Publication of SE507028C2 publication Critical patent/SE507028C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
SE9602931A 1996-08-06 1996-08-06 Ny medicinsk användning SE507028C2 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE9602931A SE507028C2 (sv) 1996-08-06 1996-08-06 Ny medicinsk användning
CA002261742A CA2261742A1 (en) 1996-08-06 1997-08-01 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
JP10507859A JP2000515543A (ja) 1996-08-06 1997-08-01 ヘルペスウイルスにより起こる感染を予防または治療するためのキトサンと組み合わされたヘパリンまたはヘパラン硫酸の使用
DE69711897T DE69711897T2 (de) 1996-08-06 1997-08-01 Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus
PCT/SE1997/001320 WO1998005341A1 (en) 1996-08-06 1997-08-01 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
NZ333925A NZ333925A (en) 1996-08-06 1997-08-01 Use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
DK97934838T DK0930885T3 (da) 1996-08-06 1997-08-01 Anvendelsen af heparin eller heparansulfat kombineret med chitosan til forebyggelsen eller behandlingen af infektioner af herpesvirus
AU37911/97A AU705189B2 (en) 1996-08-06 1997-08-01 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
CN97197038A CN1227493A (zh) 1996-08-06 1997-08-01 肝素或硫酸乙酰肝素与脱乙酰壳多糖结合用于预防或治疗由疱疹病毒引起的感染
EP97934838A EP0930885B1 (en) 1996-08-06 1997-08-01 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
AT97934838T ATE215829T1 (de) 1996-08-06 1997-08-01 Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus
ES97934838T ES2174273T3 (es) 1996-08-06 1997-08-01 Uso de heparina o heparan-sulfato en combinacion con quitosan para la prevencion o el tratamiento de infecciones causadas por virus herpes.
US09/230,021 US6207653B1 (en) 1996-08-06 1997-08-01 Use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9602931A SE507028C2 (sv) 1996-08-06 1996-08-06 Ny medicinsk användning

Publications (3)

Publication Number Publication Date
SE9602931D0 SE9602931D0 (sv) 1996-08-06
SE9602931L SE9602931L (sv) 1998-02-07
SE507028C2 true SE507028C2 (sv) 1998-03-16

Family

ID=20403528

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9602931A SE507028C2 (sv) 1996-08-06 1996-08-06 Ny medicinsk användning

Country Status (13)

Country Link
US (1) US6207653B1 (ja)
EP (1) EP0930885B1 (ja)
JP (1) JP2000515543A (ja)
CN (1) CN1227493A (ja)
AT (1) ATE215829T1 (ja)
AU (1) AU705189B2 (ja)
CA (1) CA2261742A1 (ja)
DE (1) DE69711897T2 (ja)
DK (1) DK0930885T3 (ja)
ES (1) ES2174273T3 (ja)
NZ (1) NZ333925A (ja)
SE (1) SE507028C2 (ja)
WO (1) WO1998005341A1 (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE508760C2 (sv) 1997-04-29 1998-11-02 Medicarb Ab Användning av en komposition innefattande kitosan i kombination med en polysackarid, som aktiv komponent i ett lösningsmedel, för framställning av ett spendoppningsmedel för mjölkproducerande djur
US6977248B1 (en) * 1999-08-25 2005-12-20 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
AU7070700A (en) * 1999-08-25 2001-03-19 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
SE9904289D0 (sv) * 1999-11-26 1999-11-26 Niklas Arnberg Method and camposition for the treatment of adenovairal ocular infections
US20020119949A1 (en) * 2001-02-26 2002-08-29 Asa Hellman Prophylactic teat treatment
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
EP1774971A1 (en) * 2005-10-14 2007-04-18 Advanced in Vitro Cell Technologies, S.L. Chitosan and heparin nanoparticles
RU2432187C2 (ru) 2005-12-13 2011-10-27 ЭксТера Медикал ЛЛС Метод экстракорпорального удаления из крови патогенных микробов, клеток воспаления или белков воспаления
WO2008155683A1 (en) 2007-06-18 2008-12-24 Firmenich Sa Malodor counteracting compositions and method for their use
CL2008000156A1 (es) * 2008-01-18 2008-08-01 Igloo Zone Chile S A Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel.
US8906883B2 (en) * 2009-06-10 2014-12-09 Exthera Ab Treatment of oral mucositis by administering an ionic complex of chitosan and a negatively charged polysaccharide selected from heparin, heparan sulfate and dextran sulfate
CN102740859B (zh) 2009-12-01 2016-08-10 艾克塞拉医疗公司 使用固定于表面的多糖从血液中去除细胞因子的方法
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
EP2557151B1 (en) * 2010-04-07 2017-10-04 Mitsubishi Gas Chemical Company, Inc. S-adenosyl-l-methionine-containing dry yeast composition with excellent storage stability and process for producing same
WO2011142484A1 (ja) * 2010-05-14 2011-11-17 株式会社日本触媒 ポリアルキレンイミンを含むウイルス感染症治療薬
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
EP2861273B1 (en) 2012-06-13 2017-08-23 ExThera Medical Corporation Use of heparin and carbohydrates to treat cancer
EP3013445B1 (en) 2013-06-24 2019-11-06 ExThera Medical Corporation Blood filtration system containing mannose coated substrate
JP6806563B2 (ja) 2013-11-08 2021-01-06 エクステラ・メディカル・コーポレーション 吸着媒体を使用する感染症の診断法
MX2016013873A (es) 2014-04-24 2017-03-09 Exthera Medical Corp Metodo para eliminar bacterias de la sangre usando alta velocidad de flujo.
MX2017003723A (es) 2014-09-22 2017-06-30 Exthera Medical Corp Dispositivo de hemoperfusion portatil.
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
WO2017151797A1 (en) 2016-03-02 2017-09-08 Exthera Medical Corporation Method for treating drug intoxication
KR20220009400A (ko) 2019-05-16 2022-01-24 엑스테라 메디컬 코퍼레이션 내피 글리코칼릭스 구조의 조절 방법
EP4228595A1 (en) * 2020-10-14 2023-08-23 Medoderm GmbH Liquid composition for use in the prevention or reduction of skin irritation, allergy and/or an infectious disease
WO2023044132A2 (en) * 2021-09-17 2023-03-23 Shawn Walker Use of chitosan complexes or compositions to reduce infiltration of environmental factors into the brain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU77562A1 (de) * 1977-06-17 1979-03-26 Ciba Geigy Ag Verfahren zur herstellung von neuen pharmazeutischen praeparaten
EP0240098A3 (en) 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
AU1052492A (en) 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent

Also Published As

Publication number Publication date
CA2261742A1 (en) 1998-02-12
EP0930885A1 (en) 1999-07-28
AU3791197A (en) 1998-02-25
CN1227493A (zh) 1999-09-01
DE69711897D1 (de) 2002-05-16
NZ333925A (en) 2000-07-28
US6207653B1 (en) 2001-03-27
DK0930885T3 (da) 2002-05-06
SE9602931L (sv) 1998-02-07
ES2174273T3 (es) 2002-11-01
EP0930885B1 (en) 2002-04-10
JP2000515543A (ja) 2000-11-21
ATE215829T1 (de) 2002-04-15
AU705189B2 (en) 1999-05-20
SE9602931D0 (sv) 1996-08-06
DE69711897T2 (de) 2002-08-22
WO1998005341A1 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
SE507028C2 (sv) Ny medicinsk användning
Wozniak et al. Anti-HSV1 activity of brown algal polysaccharides and possible relevance to the treatment of Alzheimer's disease
KR101569751B1 (ko) 부분 탈아세틸화 키틴 유도체의 조성물
EP1126881B1 (de) Mucoadhäsive polymere, deren verwendung sowie deren herstellungsverfahren
JPH10502665A (ja) 創傷治癒剤
DE60219653T2 (de) Pharmazeutische zusammensetzung mit chito-oligomeren
KR102256919B1 (ko) 혈액 항응고제로서 알기네이트 올리고머의 용도
Yermak et al. Carrageenan gel beads for echinochrome inclusion: Influence of structural features of carrageenan
US12558379B2 (en) Compositions and methods relating to pooled fetal support tissue
DE68904264T2 (de) Fragmente und fraktionen von heparin mit wirkung gegen hiv.
KR101905239B1 (ko) 스타필로코쿠스 아우레우스에 대한 델피니딘의 용도
US12440509B2 (en) Application of sulfated polysaccharides in resisting novel coronavirus
US20100173779A1 (en) Composition and method to stimulate growth and defense against pathogens in plants
CN114805630A (zh) 一种燕麦葡聚糖及其制备方法和应用
CN114316081B (zh) 一种具有抑制SARS-CoV-2活性的长茎葡萄蕨藻硫酸化多糖及其制备方法和应用
Ferrante et al. Synthesis and characterization of gelatin/chondroitin sulfate microgels with NaCl: Preliminary research toward wound healing applications
HK1022274A (en) The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
KR100563616B1 (ko) 베타글루칸 유도체, 그의 제조방법 및 베타글루칸유도체를 이용한 유착방지제, 그의 제조방법
US20260083771A1 (en) Biopolymers for Ophthalmic Use
Hatipoglu et al. Effect of laminarin and chitosan gel formulations on the treatment of hydrofluoric acid induced corneal burns in the rabbits.
RU2121323C1 (ru) Раствор для лечения заболеваний и повреждений роговицы "кератан с"
Rodrigues et al. Pharmaceutical application of chitosan derivatives
JP2003510283A (ja) 感染阻止のための陽性に荷電した炭水化物ポリマー
EP1842546B1 (en) Cellulose sulfate for the treatment of rhinovirus infection
WO2022137147A1 (en) Antiviral agents for prevention or treatment of pathologies caused by alpha- and/or beta-coronaviruses

Legal Events

Date Code Title Description
NUG Patent has lapsed